Torcetrapib doesn't slow atherosclerosis: study
Pfizer’s experimental compound torcetrapib did not slow progression of plaque buildup in the coronary arteries, despite raising HDL or “good” ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.